Enzyme Inhibitor Diagnostic Device for Specific Bio Marker Detection

Solution Overview

Problem

Current diagnostic methods for detecting bio markers in bodily fluids, such as circulating tumor cells, are limited by low specificity and high costs due to the use of antibody-based techniques, which also damage cells and require high sample volumes.

Innovation Solution

A diagnostic device comprising a binding agent specifically designed to bind bio markers, a linker compound, and a substrate, where the binding agent is an enzyme inhibitor that can be easily resolved, allowing for efficient detection and enrichment of bio markers on a metallic, semiconductor, or polymeric carrier.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Measurement precision

If antibody-based techniques are used for detecting bio markers, then detection capability is achieved, but specificity is limited and costs are high

Engineering Contradiction:

Improvedetection capabilityVSAvoidspecificity

Core Design Contradiction:

Measurement precisionVSReliability

Solution Approach 1:

The patent uses small molecule inhibitors as simplified copies or alternatives to antibodies for binding to target structures. These inhibitors replicate the binding function of antibodies but with higher specificity and lower cost, avoiding the non-specific binding issues that plague antibody-based methods

Inventive Principle:

Principle #26Copying

Solution Approach 2:

The patent employs small molecule inhibitors that are chemically synthesized and can be easily produced at low cost compared to antibodies. These inhibitors are not biological entities that require complex purification and storage conditions, making them cheaper and more stable alternatives for diagnostic applications

Inventive Principle:

Principle #27Cheap short-living objects (Disposable)

2Measurement precision

If antibody-based techniques are used for detecting bio markers, then detection capability is achieved, but sample volume required is very high

Engineering Contradiction:

Improvedetection capabilityVSAvoidsample volume

Core Design Contradiction:

Measurement precisionVSQuantity of substance

Solution Approach 1:

The patent changes the binding parameters by using small molecule inhibitors with high affinity and specificity for target structures. This allows effective binding and detection with much smaller sample volumes compared to antibody-based methods, as the inhibitors can achieve saturation binding at lower concentrations

Inventive Principle:

Principle #35Parameter changes

3Measurement precision

If antibody-based techniques are used for detecting bio markers, then detection capability is achieved, but costs are high

Engineering Contradiction:

Improvedetection capabilityVSAvoidcosts

Core Design Contradiction:

Measurement precisionVSEase of manufacture

Solution Approach 1:

The patent employs small molecule inhibitors that are chemically synthesized and can be easily produced at low cost compared to antibodies. These inhibitors are not biological entities that require complex purification and storage conditions, making them cheaper and more stable alternatives for diagnostic applications

Inventive Principle:

Principle #27Cheap short-living objects (Disposable)

Solution Approach 2:

The patent uses small molecule inhibitors as simplified copies or alternatives to antibodies for binding to target structures. These inhibitors replicate the binding function of antibodies but with higher specificity and lower cost, avoiding the non-specific binding issues that plague antibody-based methods

Inventive Principle:

Principle #26Copying

4Measurement precision

If antibody-based techniques are used for detecting bio markers, then detection capability is achieved, but cells are damaged

Engineering Contradiction:

Improvedetection capabilityVSAvoidcell damage

Core Design Contradiction:

Measurement precisionVSObject-affected harmful factors

Solution Approach 1:

The patent uses small molecule inhibitors as simplified copies or alternatives to antibodies for binding to target structures. These inhibitors replicate the binding function of antibodies but with higher specificity and lower cost, avoiding the non-specific binding issues that plague antibody-based methods

Inventive Principle:

Principle #26Copying

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The device provides improved specificity and lower costs for detecting rare bio markers, with a lower risk of side effects and no damage to cells, enabling efficient detection of disease-related target structures like cancer or infections.

Implementation Method 1

a binding agent that specifically binds said bio marker, wherein the binding agent is an enzyme inhibitor

Methodology Applied

Scientific EffectEnzyme-inhibitor binding: Enzyme

Data Source

PatentUS10352931B2Diagnostic device for the detection of disease related target structures

Publication Date: 2019.07.16 GILUPI

AI summary

The present invention provides a diagnostic device allowing highly specific and efficient in vivo and/or in vitro detection of a bio marker in a broad range of bodily fluids or tissues. The diagnostic device is composed of a binding agent that specifically binds a bio marker present in the bodily fluid linked by a linker compound or layer to the substrate, which includes a metallic, a semiconductor, or a polymeric carrier. The present invention further provides methods using said device for the detection of bio markers, as well as kits comprising said device and suitable ingredients for the detections of bio markers in a bodily fluid. Furthermore, the invention provides suitable in vivo and in vitro applications of said binding agent for the detection of specific disease-related target structures.